Professor | Page 328 of 349

Contraception :: IUC is a preferred contraceptive of female

Intrauterine contraception (IUC) is very effective, with a failure rate of less than one percent (similar to that of sterilization), which is one reason why many female ob/gyns choose this method of birth control for themselves. In fact, research shows that female ob/gyns are nine times more likely to choose an IUC for themselves compared with women in general. Misinformation and misperceptions about the IUC may have contributed to its limited use among women in the U.S. to date.

Constipation :: Unfounded fear of addiction prevents laxative use

Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show that many people wrongly fear that laxatives are addictive and that their use for long periods of time actually causes constipation.1,2

Ulcerative Colitis :: Mesalamine associated with rapid mucosal healing in ulcerative colitis patients

Combined data analysis from two trials demonstrated that treatment success is associated with mucosal healing in patients with moderately active ulcerative colitis who received either 2.4 or 4.8 grams of mesalamine per day. By 6 weeks, 67% of patients achieved both treatment success and mucosal healing, while only 5% achieved treatment success without demonstrating mucosal healing. The results were presented by University of Chicago researcher David T. Rubin, MD, at the annual scientific meeting of the American College of Gastroenterology (ACG).

Ulcerative Colitis :: Adherence to ulcerative colitis medications is not affected by drug formulation or dosing regimen

Poor adherence to medication is a recognized medical problem, costing an estimated $100 billion a year in the United States.(i) New data show that while there is a steady decline in adherence to medications for ulcerative colitis (UC), drug formulation and the number of pills taken each day do not affect long-term adherence. The data were presented today at the annual scientific meeting of the American College of Gastroenterology by University of Chicago researcher Sunanda Kane, M.D.

Dyspepsia :: Zelnorm, tegaserod maleate for relief of multiple symptoms of dyspepsia – Novartis

The gastrointestinal medicine Zelnorm? (tegaserod maleate) has demonstrated potential benefits in helping patients with the multiple symptoms of a common digestive disorder called dysmotility-type dyspepsia[1], according to new Phase III data presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.

Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B – Novartis

Novartis announced the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death.

HIV :: Most HIV infected individuals with inadequate outpatient medical care

In a first-of-its-kind study, UCLA researchers have shown that segments of the HIV-infected population who have little to no consistent outpatient medical care ? and yet are most in need of such services ? are overwhelmingly minorities, the poor and substance abusers.

Imaging :: MRI Scans by Remote Control

UCLA radiologists and Siemens Medical Solutions have jointly developed remote-control software that enables an off-site imaging expert to log onto a personal computer and operate a magnetic resonance imaging (MRI) machine by remote control. Reported in the November issue of Radiology, the study found that the quality of the remote scans were superior to onsite scans by a less experienced technologist, suggesting options for helping facilities or regions with limited medical staff and expertise.

Crohn’s Disease :: Promising results in tough-to-treat crohn’s disease patients

Abbott announced results from a study showing HUMIRA? (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn’s disease who lost response to, or were intolerant to, infliximab therapy. The data is being presented simultaneously at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.

Diet :: Trial aims to find out which diets work

A new Australian clinical trial hopes to answer the question about which diets work and why. Healthy volunteers will be kept in controlled laboratory conditions for a week and fed diets with different levels of protein.